Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
Christopher J VandenBusscheDerek B AllisonMindy K GrahamVivek CharuAnne Marie LennonChristopher L WolfgangRalph H HrubanChristopher M HeaphyPublished in: Cancer cytopathology (2017)
Both ALT and loss of ATRX/DAXX can be accurately performed on FNA specimens with adequate material. Because ALT is a fundamental mechanism of pathogenesis, the ability to determine ALT in small biospecimens has implications for the design of clinical trials. Cancer Cytopathol 2017;125:544-51. © 2017 American Cancer Society.